Sanofi-Aventis S.A. (SNY)
$43.41 0.00 (0.00%)
17:16 EST SNY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 107.59B
PE Ratio 29.04
Volume (Avg. Vol.)
Day's Range 43.41 - 43.41
52-Week Range -
Dividend & Yield 1.86 (4.29%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. News
- From InvestorPlace
- From the Web
GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.
Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Despite their indispensable demand, pharmaceutical stocks face tough roadblocks as competition for breakthrough drugs intensifies.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
SNY stock beat on earnings and missed on revenue, but sales of newer drugs as well as a low P/E and a high dividend show promise for Sanofi.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Put these tickers on a list of stocks to buy here in the midst of market-wide carnage. They're likely to recover first and best once the selloff settles.
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe.
Sanofi SA (NYSE:SNY) is one of the 781 companies in the GICS Health Care sector, and a member of the 134 company Pharmaceuticals GICS industry group within this sector. The market value of SNY is $115.8 billion which falls in the top decile in its industry group. The ranking for SNY by Portfolio Grader places it 34 among the 134 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 206 among the 781 companies in the sector, and number 1,262 in the nearly 5,000 company Portfolio Grader universe.
From Real Money
From Seeking Alpha
Following through on President Trump's Executive Order in July aimed at cutting U.S. drug costs via importation, the FDA issues its final rule on allowing agency-authorized programs to import medicines, including biologics, from Canada under certain conditions that ensure safety.The guidance describes procedures drug makers can follow, including obtaining a National Drug Code (NDC), to facilitate the importation of prescription drugs and biologics that are FDA-approved, manufactured abroad, authorized for sale in any foreign country and originally intended for sale in that foreign country.The rule allows states (including the District of Columbia and territories), Indian tribes and — in certain future circumstances — pharmacists and wholesalers, to submit importation program proposals to the FDA for review and authorization.
Navellier RatingsPowered by Portfolio Grader